Top > Search of International Patents > ANTIVIRAL DRUG FOR SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME

ANTIVIRAL DRUG FOR SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME

Foreign code F180009522
File No. (S2017-0259-N0)
Posted date Nov 2, 2018
Country WIPO
International application number 2018JP000887
International publication number WO 2018135449
Date of international filing Jan 16, 2018
Date of international publication Jul 26, 2018
Priority data
  • P2017-007507 (Jan 19, 2017) JP
Title ANTIVIRAL DRUG FOR SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME
Abstract The present invention pertains to an antiviral drug for severe fever with thrombocytopenia syndrome, which contains a compound represented by formula (I) or a salt thereof, or a solvate of the compound or salt (In the formula, R1 and R2 are the same or different from each other, and each represents a substituted or unsubstituted C1-10 alkyl group, R1 and R2 may form a substituted or unsubstituted 5- or 6-member ring in conjunction with an adjacent nitrogen atom, and X represent a halogen atom.)
Outline of related art and contending technology BACKGROUND ART
Thermally severe thrombocytopenia (severe fever with thrombocytopenia syndrome syndrome; SFTS) Chinese year 2011 is published by researchers hemorrhagicbunyaviruses family genus phlebovirus SFTSV(severe fever with thrombocytopenia syndrome virus) miticidal classified by the new virus mediated infection.Was first reported in regard to 2013, the mortality rate is very high infection.Current, as a center in the western part of, the current 30 November 2016 226 patients have been reported, and one of the death of the name 52.
On the other hand, amodiaquine is, already approved for clinical use as anti-malarial drugs and, further, amodiaquine or 7-chloro compounds as claimed in-4-effective Xiaozhi Parkinson's disease has been known.However, such as amodiaquine 7-chloro compound SFTSV-4-as claimed in terms of the relationship-active has never been reported so far.
Scope of claims (In Japanese)請求の範囲
[請求項1]
 下記式(I):
[化1]
(式中、R 1及びR 2は同一又は異なり、置換又は無置換のC 1-10-アルキル基であり、R 1及びR 2は、隣接する窒素原子と共同して、置換又は非置換の5員環又は6員環を形成してもよく;Xはハロゲン原子である。)
で示される化合物もしくはその塩又はそれらの溶媒和物を含有する抗重症熱性血小板減少症候群ウイルス薬。
[請求項2]
 前記式(I)において、R 1及びR 2は同一又は異なり、置換又は無置換のC 1-6-アルキル基であり、R 1及びR 2は、隣接する窒素原子と共同して、置換又は非置換の5員環又は6員環を形成してもよく;Xはハロゲン原子である請求項1記載の抗重症熱性血小板減少症候群ウイルス薬。
[請求項3]
 重症熱性血小板減少症候群の予防又は治療に用いられる請求項1又は2記載の抗重症熱性血小板減少症候群ウイルス薬。
[請求項4]
 下記式(Ia):
[化2]
(式中、R 1a及びR 2aは、メチル基とC 1-10-アルキル基、エチル基とC 3-10-アルキル基、又はエチル基と2-ヒドロキシエチル基であり、R 1a及びR 2aは、隣接する窒素原子と共同して、置換又は非置換の5員環又は6員環を形成してもよく;X aはヨウ素原子又はフッ素原子であり;X aがフッ素原子の場合、R 1a及びR 2aは、エチル基とエチル基であってもよい。)
で示される化合物もしくはその塩又はそれらの溶媒和物。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KAGOSHIMA UNIVERSITY
  • Inventor
  • BABA Masanori
  • TOYAMA Masaaki
  • SAKAKIBARA Norikazu
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close